Sequencing tyrosine kinase inhibitors or immediately switching to mTOR inhibitors in advanced kidney cancer: A critical review

Research output: Contribution to journalArticle

Abstract

Since the approval of Sorafenib and Sunitinib, many advanced renal cell carcinoma (aRCC) patients have been empirically treated by using the two tyrosine kinase inhibitors (TKIs) in sequence with the aim of prolonging the stabilization of their disease. This strategy is supported by the results of few small prospective and several small retrospective studies, all indicating that there is limited or no cross-resistance between the two TKIs. On the other hand, data from the randomized, placebo-controlled, phase III RECORD-1 trial showed that the mTOR inhibitor Everolimus is as effective after one TKI as it is after both TKIs. In this review we comment all the available evidence on this important subject*irrespective of its formal relevance*critically discussing the results obtained so far, with the aim of helping us to make the best clinical decisions possible.

Original languageEnglish
JournalEuropean journal of Clinical and Medical Oncology
Volume2
Issue number4
Publication statusPublished - 2010

Fingerprint

Kidney Neoplasms
Protein-Tyrosine Kinases
Renal Cell Carcinoma
Retrospective Studies
Placebos

Keywords

  • Everolimus
  • Renal cell carcinoma
  • Sequential treatment
  • Sorafenib
  • Sunitinib

ASJC Scopus subject areas

  • Oncology

Cite this

@article{6c45c925c5fb402fa52818aff4d62c52,
title = "Sequencing tyrosine kinase inhibitors or immediately switching to mTOR inhibitors in advanced kidney cancer: A critical review",
abstract = "Since the approval of Sorafenib and Sunitinib, many advanced renal cell carcinoma (aRCC) patients have been empirically treated by using the two tyrosine kinase inhibitors (TKIs) in sequence with the aim of prolonging the stabilization of their disease. This strategy is supported by the results of few small prospective and several small retrospective studies, all indicating that there is limited or no cross-resistance between the two TKIs. On the other hand, data from the randomized, placebo-controlled, phase III RECORD-1 trial showed that the mTOR inhibitor Everolimus is as effective after one TKI as it is after both TKIs. In this review we comment all the available evidence on this important subject*irrespective of its formal relevance*critically discussing the results obtained so far, with the aim of helping us to make the best clinical decisions possible.",
keywords = "Everolimus, Renal cell carcinoma, Sequential treatment, Sorafenib, Sunitinib",
author = "Camillo Porta and Chiara Paglino and Ilaria Imarisio",
year = "2010",
language = "English",
volume = "2",
journal = "European journal of Clinical and Medical Oncology",
issn = "1759-8958",
publisher = "San Lucas Medical",
number = "4",

}

TY - JOUR

T1 - Sequencing tyrosine kinase inhibitors or immediately switching to mTOR inhibitors in advanced kidney cancer

T2 - A critical review

AU - Porta, Camillo

AU - Paglino, Chiara

AU - Imarisio, Ilaria

PY - 2010

Y1 - 2010

N2 - Since the approval of Sorafenib and Sunitinib, many advanced renal cell carcinoma (aRCC) patients have been empirically treated by using the two tyrosine kinase inhibitors (TKIs) in sequence with the aim of prolonging the stabilization of their disease. This strategy is supported by the results of few small prospective and several small retrospective studies, all indicating that there is limited or no cross-resistance between the two TKIs. On the other hand, data from the randomized, placebo-controlled, phase III RECORD-1 trial showed that the mTOR inhibitor Everolimus is as effective after one TKI as it is after both TKIs. In this review we comment all the available evidence on this important subject*irrespective of its formal relevance*critically discussing the results obtained so far, with the aim of helping us to make the best clinical decisions possible.

AB - Since the approval of Sorafenib and Sunitinib, many advanced renal cell carcinoma (aRCC) patients have been empirically treated by using the two tyrosine kinase inhibitors (TKIs) in sequence with the aim of prolonging the stabilization of their disease. This strategy is supported by the results of few small prospective and several small retrospective studies, all indicating that there is limited or no cross-resistance between the two TKIs. On the other hand, data from the randomized, placebo-controlled, phase III RECORD-1 trial showed that the mTOR inhibitor Everolimus is as effective after one TKI as it is after both TKIs. In this review we comment all the available evidence on this important subject*irrespective of its formal relevance*critically discussing the results obtained so far, with the aim of helping us to make the best clinical decisions possible.

KW - Everolimus

KW - Renal cell carcinoma

KW - Sequential treatment

KW - Sorafenib

KW - Sunitinib

UR - http://www.scopus.com/inward/record.url?scp=79956083945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956083945&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:79956083945

VL - 2

JO - European journal of Clinical and Medical Oncology

JF - European journal of Clinical and Medical Oncology

SN - 1759-8958

IS - 4

ER -